Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

2.1 Durvalumab (Imfinzi, AstraZeneca) is 'indicated for the treatment of locally advanced, unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for durvalumab.

2.3 Ths list price of durvalumab is £2,466 per 500 mg per 10‑ml infusion vial (excluding VAT; BNF online, accessed April 2022).

2.4 The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.